Glaxo–SmithKline merger: sooner than later? - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glaxo–SmithKline merger: sooner than later?

Aug 14, 2000

Glaxo India and SmithKline Pharma, it seems, are proceeding apace with their merger in India much sooner than expected. Though the details are not known, one indication of this came at the analysts meet of Glaxo India when the Managing Director Mr. Khusrokhan refused to talk about the merger saying that it could impact the share prices of the two companies. We have tried to hypothecate about the merger ratio between the two companies assuming of course that Burroughs Wellcome and SmithKline Consumer are kept out of the merger temporarily. While the Glaxo management has clearly indicated that the amalgamation with Burroughs has been put on to the back burner, the decision about SmithKline Consumer is likely to be taken at the global headquarters since Glaxo has already sold its foods portfolio (comprising ‘Farex’ and ‘Glucon D’) worldwide. Even in India the food division was sold to Heinz. SmithKline abroad is more of a pharma company with the major operations of ‘Horlicks’ in the UK apart from a sizeable presence in India.

Both the companies came out of a trough in the second quarter and reported outstanding results despite an adverse industry environment. While Glaxo reported a 27% jump in the topline in the second quarter, SmithKline also reported a 50% jump at the pre–tax level. And this despite a fall in the topline!

If one were to make a forecast the second half keeping in mind the forecast made by Mr. Khusrokhan (he spoke a 15% growth, for the full year at best), Glaxo would end up reporting a net in the range of Rs 800m, SmithKline would in all probability end up with a net in the range of of Rs 200 m.

Assuming a 1:2.5 ratio (i.e. 2.5 shares of SmithKline for every 1 share of Glaxo), the merged entity would end up with an equity of around Rs 716 m (post merger) and a per share earnings of Rs.13.89.

At a price earnings of around 40, the merged company could quote at levels of Rs 560–570. While Glaxo currently quotes at a price of Rs 470, SmithKline Pharma is quoting at the price of 158. Thus if a merger were to materialise the market prices are actually indicative of a 1:3 ratio (i.e. one share of Glaxo for every three of SmithKline Pharma). This could be taking into account the cash and the value of the properties that Glaxo holds. (Glaxo holds cash and marketable investments of almost Rs 600 m besides valuable real estate at Mumbai, which it has leased out.)

Equitymaster requests your view! Post a comment on "Glaxo–SmithKline merger: sooner than later?". Click here!

  

More Views on News

GSK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 26, 2021 | Updated on Oct 26, 2021

Here's an analysis of the annual report of GSK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

The Biggest Winners and Losers in India's Transition to Electric Vehicles (Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Dec 7, 2021 12:00 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS